Methods & Materials: Between October 2017 and April 2018, six patients (age range: 18-60) with a total of eight lesions (lesion size range: 0.5-2.0 cm as measured on ultrasound) with imaging features suggestive of a fibroadenoma were imaged. All lesions were ultimately either biopsy-proven or clinically-confirmed to be benign. Each patient underwent an IRB-approved dynamic contrast-enhanced MRI scan utilizing a novel dual-dose injection protocol. Pre-contrast scans including T2-weighted scans and high temporal resolutions scans were obtained. Next, 15% of the contrast was administered with post-contrast imaging including: Standard T1 weighted scans and high temporal resolution scans.
Approximately 10 minutes later, 85% of the contrast was administered with repeat post-contrast imaging similar to prior. Two radiologists reviewed the low-dose MR images and high-dose MR images to evaluate for: Lesion conspicuity, imaging characteristics and enhancement kinetics.